1
|
Lu MN, Wang D, Ye CJ, Yan GJ, Song JF, Shi XY, Li SS, Liu LN, Zhang HX, Dong XH, Hu T, Wang XY, Xiyang YB. Navβ2 Intracellular Fragments Contribute to Aβ1-42-Induced Cognitive Impairment and Synaptic Deficit Through Transcriptional Suppression of BDNF. Mol Neurobiol 2024:10.1007/s12035-024-04317-y. [PMID: 38965172 DOI: 10.1007/s12035-024-04317-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Accepted: 06/17/2024] [Indexed: 07/06/2024]
Abstract
A pathological hallmark of Alzheimer's disease (AD) is the region-specific accumulation of the amyloid-beta protein (Aβ), which triggers aberrant neuronal excitability, synaptic impairment, and progressive cognitive decline. Previous works have demonstrated that Aβ pathology induced aberrant elevation in the levels and excessive enzymatic hydrolysis of voltage-gated sodium channel type 2 beta subunit (Navβ2) in the brain of AD models, accompanied by alteration in excitability of hippocampal neurons, synaptic deficits, and subsequently, cognitive dysfunction. However, the mechanism is unclear. In this research, by employing cell models treated with toxic Aβ1-42 and AD mice, the possible effects and potential mechanisms induced by Navβ2. The results reveal that Aβ1-42 induces remarkable increases in Navβ2 intracellular domain (Navβ2-ICD) and decreases in both BDNF exons and protein levels, as well as phosphorylated tropomyosin-related kinase B (pTrkB) expression in cells and mice, coupled with cognitive impairments, synaptic deficits, and aberrant neuronal excitability. Administration with exogenous Navβ2-ICD further enhances these effects induced by Aβ1-42, while interfering the generation of Navβ2-ICD and/or complementing BDNF neutralize the Navβ2-ICD-conducted effects. Luciferase reporter assay verifies that Navβ2-ICD regulates BDNF transcription and expression by targeting its promoter. Collectively, our findings partially elucidate that abnormal enzymatic hydrolysis of Navβ2 induced by Aβ1-42-associated AD pathology leads to intracellular Navβ2-ICD overload, which may responsible to abnormal neuronal excitability, synaptic deficit, and cognition dysfunction, through its transcriptional suppression on BDNF. Therefore, this work supplies novel evidences that Navβ2 plays crucial roles in the occurrence and progression of cognitive impairment of AD by transcriptional regulatory activity of its cleaved ICD.
Collapse
Affiliation(s)
- Min-Nan Lu
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
- Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Dan Wang
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Chen-Jun Ye
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Guo-Ji Yan
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Jing-Feng Song
- School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Xin-Ying Shi
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Shan-Shan Li
- Experimental Teaching Center, Basic Medical College, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Li-Na Liu
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Hui-Xiang Zhang
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Xiao-Han Dong
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Tao Hu
- Department of Laboratory Medicine, The Third People's Hospital of Yunnan Province, Kunming, 650000, Yunnan, China
| | - Xu-Yang Wang
- Department of Neurosurgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China
| | - Yan-Bin Xiyang
- Institute of Neuroscience, Kunming Medical University, Kunming, 650500, Yunnan, China.
| |
Collapse
|
2
|
Sürücü Kara İ, Köse E, Çavdarlı B, Eminoğlu FT. Neuronal ceroid lipofuscinosis type 11 diagnosed patient with bi-allelic variants in GRN gene: case report and review of literature. J Pediatr Endocrinol Metab 2024; 37:280-288. [PMID: 38253347 DOI: 10.1515/jpem-2023-0411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 01/04/2024] [Indexed: 01/24/2024]
Abstract
OBJECTIVES Neuronal ceroid lipofuscinosis type 11 (NCL11) is a rare disease that presents with progressive cognitive decline, epilepsy, visual impairment, retinal atrophy, cerebellar ataxia and cerebellar atrophy. We present herein a case of NCL11 in a patient diagnosed with neuromotor developmental delay, epilepsy, bronchiolitis obliterans and hypothyroidism. CASE PRESENTATION A 4-year-old male patient was admitted to our clinic with global developmental delay and a medical history that included recurrent hospitalizations for pneumonia at the age of 17 days, and in months 4, 5 and 7. Family history revealed a brother with similar clinical findings (recurrent pneumonia, hypothyroidism, hypotonicity, swallowing dysfunction and neuromotor delay) who died from pneumonia at the age of 22 months. Computed tomography of the thorax was consistent with bronchiolitis obliterans, while epileptic discharges were identified on electroencephalogram with a high incidence of bilateral fronto-centro-temporal and generalized spike-wave activity but no photoparoxysmal response. Cranial MRI revealed T2 hyperintense areas in the occipital periventricular white matter and volume loss in the white matter, a thin corpus callosum and vermis atrophy. A whole-exome sequencing molecular analysis revealed compound heterozygous c.430G>A (p.Asp144Asn) and c.415T>C (p.Cys139Arg) variants in the GRN gene. CONCLUSIONS The presented case indicates that NCL11 should be taken into account in patients with epilepsy and neurodegenerative diseases.
Collapse
Affiliation(s)
- İlknur Sürücü Kara
- Department of Pediatric Metabolism, Faculty of Medicine, Ankara University, Ankara, Türkiye
| | - Engin Köse
- Department of Pediatric Metabolism, Faculty of Medicine, Ankara University, Ankara, Türkiye
- Ankara University Rare Diseases Application and Research Center, Ankara, Türkiye
| | - Büşranur Çavdarlı
- Department of Medical Genetics, Ankara Bilkent City Hospital, Ankara, Türkiye
| | - Fatma Tuba Eminoğlu
- Department of Pediatric Metabolism, Faculty of Medicine, Ankara University, Ankara, Türkiye
- Ankara University Rare Diseases Application and Research Center, Ankara, Türkiye
| |
Collapse
|
3
|
Hsiao-Nakamoto J, Chiu CL, VandeVrede L, Ravi R, Vandenberg B, De Groot J, Tsogtbaatar B, Fang M, Auger P, Gould NS, Marchioni F, Powers CA, Davis SS, Suh JH, Alkabsh J, Heuer HW, Lago AL, Scearce-Levie K, Seeley WW, Boeve BF, Rosen HJ, Berger A, Tsai R, Di Paolo G, Boxer AL, Bhalla A, Huang F. Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal Dementia. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.02.09.579529. [PMID: 38405775 PMCID: PMC10888909 DOI: 10.1101/2024.02.09.579529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/27/2024]
Abstract
Background Frontotemporal dementia (FTD) is the most common cause of early-onset dementia with 10-20% of cases caused by mutations in one of three genes: GRN, C9orf72, or MAPT. To effectively develop therapeutics for FTD, the identification and characterization of biomarkers to understand disease pathogenesis and evaluate the impact of specific therapeutic strategies on the target biology as well as the underlying disease pathology are essential. Moreover, tracking the longitudinal changes of these biomarkers throughout disease progression is crucial to discern their correlation with clinical manifestations for potential prognostic usage. Methods We conducted a comprehensive investigation of biomarkers indicative of lysosomal biology, glial cell activation, synaptic and neuronal health in cerebrospinal fluid (CSF) and plasma from non-carrier controls, sporadic FTD (symptomatic non-carriers) and symptomatic carriers of mutations in GRN, C9orf72, or MAPT, as well as asymptomatic GRN mutation carriers. We also assessed the longitudinal changes of biomarkers in GRN mutation carriers. Furthermore, we examined biomarker levels in disease impacted brain regions including middle temporal gyrus (MTG) and superior frontal gyrus (SFG) and disease-unaffected inferior occipital gyrus (IOG) from sporadic FTD and symptomatic GRN carriers. Results We confirmed glucosylsphingosine (GlcSph), a lysosomal biomarker regulated by progranulin, was elevated in the plasma from GRN mutation carriers, both symptomatic and asymptomatic. GlcSph and other lysosomal biomarkers such as ganglioside GM2 and globoside GB3 were increased in the disease affected SFG and MTG regions from sporadic FTD and symptomatic GRN mutation carriers, but not in the IOG, compared to the same brain regions from controls. The glial biomarkers GFAP in plasma and YKL40 in CSF were elevated in asymptomatic GRN carriers, and all symptomatic groups, except the symptomatic C9orf72 mutation group. YKL40 was also increased in SFG and MTG regions from sporadic FTD and symptomatic GRN mutation carriers. Neuronal injury and degeneration biomarkers NfL in CSF and plasma, and UCHL1 in CSF were elevated in patients with all forms of FTD. Synaptic biomarkers NPTXR, NPTX1/2, and VGF were reduced in CSF from patients with all forms of FTD, with the most pronounced reductions observed in symptomatic MAPT mutation carriers. Furthermore, we demonstrated plasma NfL was significantly positively correlated with disease severity as measured by CDR+NACC FTLD SB in genetic forms of FTD and CSF NPTXR was significantly negatively correlated with CDR+NACC FTLD SB in symptomatic GRN and MAPT mutation carriers. Conclusions In conclusion, our comprehensive investigation replicated alterations in biofluid biomarkers indicative of lysosomal function, glial activation, synaptic and neuronal health across sporadic and genetic forms of FTD and unveiled novel insights into the dysregulation of these biomarkers within brain tissues from patients with GRN mutations. The observed correlations between biomarkers and disease severity open promising avenues for prognostic applications and for indicators of drug efficacy in clinical trials. Our data also implicated a complicated relationship between biofluid and tissue biomarker changes and future investigations should delve into the mechanistic underpinnings of these biomarkers, which will serve as a foundation for the development of targeted therapeutics for FTD.
Collapse
Affiliation(s)
- Jennifer Hsiao-Nakamoto
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- These authors contributed equally
| | - Chi-Lu Chiu
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- These authors contributed equally
| | - Lawren VandeVrede
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA
| | - Ritesh Ravi
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Brittany Vandenberg
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- Present address: Brittany Vandenberg, Washington State University, Pullman, WA 99164, USA
| | - Jack De Groot
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- Present address: Jack DeGroot: Prime Medicine Inc., Cambridge, MA 02139, USA
| | | | - Meng Fang
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Paul Auger
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- Present address: Paul Auger: Nurix Therapeutics, San Francisco, CA 94158, USA
| | - Neal S Gould
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Filippo Marchioni
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Casey A Powers
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- Present address: Casey A. Powers: Stanford University, Stanford, CA 94305, USA
| | - Sonnet S Davis
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Jung H Suh
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Jamal Alkabsh
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Hilary W Heuer
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA
| | - Argentina Lario Lago
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA
| | - Kimberly Scearce-Levie
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- Present address: Kimberly Scearce-Levie: Cajal Neuroscience, Seattle, WA 98109, USA
| | - William W Seeley
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA
| | - Bradley F Boeve
- Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
| | - Howard J Rosen
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA
| | - Amy Berger
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Richard Tsai
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Gilbert Di Paolo
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
| | - Adam L Boxer
- Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA
- These authors contributed equally
| | - Akhil Bhalla
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- These authors contributed equally
| | - Fen Huang
- Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA
- These authors contributed equally
| |
Collapse
|